Bozorgmehr, F., Chung, I., Christopoulos, P., Krisam, J., Schneider, M., Brückner, L. M., . . . Rieken, S. (2023). Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy$dstudy protocol of the TRADE-hypo trial. BMC cancer, 23(1), . https://doi.org/10.1186/s12885-023-11270-x
Chicago-Zitierstil (17. Ausg.)Bozorgmehr, Farastuk, Inn Chung, Petros Christopoulos, Johannes Krisam, Marc Schneider, Lena Marie Brückner, Daniel Wilhelm Müller, Michael Thomas, und Stefan Rieken. "Correction: Thoracic Radiotherapy Plus Durvalumab in Elderly And/or Frail NSCLC Stage III Patients Unfit for Chemotherapy - Employing Optimized (hypofractionated) Radiotherapy to Foster Durvalumab Efficacy$dstudy Protocol of the TRADE-hypo Trial." BMC Cancer 23, no. 1 (2023). https://doi.org/10.1186/s12885-023-11270-x.
MLA-Zitierstil (9. Ausg.)Bozorgmehr, Farastuk, et al. "Correction: Thoracic Radiotherapy Plus Durvalumab in Elderly And/or Frail NSCLC Stage III Patients Unfit for Chemotherapy - Employing Optimized (hypofractionated) Radiotherapy to Foster Durvalumab Efficacy$dstudy Protocol of the TRADE-hypo Trial." BMC Cancer, vol. 23, no. 1, 2023, https://doi.org/10.1186/s12885-023-11270-x.